Department of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA.
Neuro Oncol. 2023 Dec 8;25(12):2136-2149. doi: 10.1093/neuonc/noad136.
Glioblastoma (GBM) is among the deadliest malignancies facing modern oncology. While our understanding of certain aspects of GBM biology has significantly increased over the last decade, other aspects, such as the role of bioactive metals in GBM progression, remain understudied. Iron is the most abundant transition metal found within the earth's crust and plays an intricate role in human physiology owing to its ability to participate in oxidation-reduction reactions. The importance of iron homeostasis in human physiology is apparent when examining the clinical consequences of iron deficiency or iron overload. Despite this, the role of iron in GBM progression has not been well described. Here, we review and synthesize the existing literature examining iron's role in GBM progression and patient outcomes, as well as provide a survey of iron's effects on the major cell types found within the GBM microenvironment at the molecular and cellular level. Iron represents an accessible target given the availability of already approved iron supplements and chelators. Improving our understanding of iron's role in GBM biology may pave the way for iron-modulating approaches to improve patient outcomes.
胶质母细胞瘤(GBM)是现代肿瘤学面临的最致命的恶性肿瘤之一。尽管我们对 GBM 生物学的某些方面的理解在过去十年中显著提高,但其他方面,如生物活性金属在 GBM 进展中的作用,仍未得到充分研究。铁是地壳中含量最丰富的过渡金属,由于其参与氧化还原反应的能力,在人体生理学中发挥着复杂的作用。当研究缺铁或铁过载的临床后果时,铁在人体生理学中的平衡的重要性就显而易见了。尽管如此,铁在 GBM 进展中的作用尚未得到很好的描述。在这里,我们回顾并综合了现有的文献,研究了铁在 GBM 进展和患者预后中的作用,并对铁在 GBM 微环境中主要细胞类型的分子和细胞水平上的作用进行了综述。鉴于现有的铁补充剂和螯合剂已经获得批准,铁是一个易于接近的靶点。提高我们对铁在 GBM 生物学中作用的理解,可能为铁调节方法改善患者预后铺平道路。
Neuro Oncol. 2023-12-8
Int J Biol Macromol. 2024-10
Trends Endocrinol Metab. 2015-4-27
Cancer Med. 2022-10
Crit Rev Clin Lab Sci. 2008
Semin Nephrol. 2016-1
Clin Transl Oncol. 2011-2
Rev Med Brux. 2013-9
Toxicol Appl Pharmacol. 2005-1-15
FASEB J. 2023-12
J Cancer Res Clin Oncol. 2023-9
Exp Cell Res. 2023-3-1
J Clin Invest. 2023-1-3
Sci Adv. 2022-10-7
Exp Mol Med. 2022-10